Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model (IMRCC), in patients (pt) treated with pazopanib (Pz) as first line for metastatic renal carcinoma (mRC): First results of the SOGUG SPAZO study
![Thumbnail](/xmlui/themes/Mirage2//images/thumbnails/thumn_cientif.png)
Date issued
2015Journal title
Journal Of Clinical Oncology
Type of content
Publicación de congreso
![](/xmlui/themes/Mirage2//images/final_lines.png)